Clinical trials: Membranous
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
Exercise-induced Joint Pain, Exercise-induced Joint Stiffness
NEM® + BIOCURC® Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women
This study is intended to evaluate the combined effects of the dietary supplement NEM® brand eggshell membrane and BIOCURC® brand bioavailable curcumin versus placebo in reducing exercise-induced joint pain, stiffness \&…
- Conditions
- Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Joint Cartilage Turnover
- Trial name
- NCT03769857
- Testing
- NEM® + BIOCURC®
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- ESM Technologies, LLC
Intra-amniotic Infection
Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes
The purpose of this study is to collect clinical specimens and corresponding clinical data to develop a non-invasive test for detection of intra-amniotic infection and prediction of preterm birth in women and intact amniotic…
- Trial name
- IAI (NCT00700219)
- Where
- 21 sites in United States
- Volunteers
- 900 people
- Sponsor
- ProteoGenix, Inc.
Diabetic Foot Ulcer, Foot Ulcer Chronic
Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
The study is a multicenter, prospective, controlled modified multi-platform trial assessing the efficacy of human placental membrane products and standard of care in the management of nonhealing diabetic foot ulcers and venous…
- Conditions
- Diabetic Foot Ulcer, Foot Ulcer Chronic, DFU, Ulcer Foot
- Trial name
- BIORESCUE (NCT07364630)
- Testing
- Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- BioLab Holdings
Idiopathic Membranous Nephropathy
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy…
- Trial name
- NCT04154787
- Testing
- LNP023, Rituximab
- Where
- 18 sites in Argentina, China and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Vaginal Atrophy
Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women
Up to 50% of all postmenopausal women, experience vaginal drynes, i.e. vaginal atrophy is a consequence due to the lack of estrogen.
- Trial name
- OXYPEP002 (NCT01987804)
- Testing
- Oxytocin 100 i.u., Oxytocin 400 i.u.
- Where
- Sweden
- Volunteers
- 64 people
- Sponsor
- PepTonic Medical AB
Metastatic Castration-resistant Prostate Cancer
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells…
- Trial name
- NCT04227275
- Testing
- CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Tceleron Therapeutics, Inc.
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM EU (NCT07210463)
- Testing
- NT 201
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Merz Aesthetics GmbH
Partial Nephrectomy, Kidney Cancer
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
After partial nephrectomy, kidney function decreases by about 10% overall and by about 20% in the operated kidney. This is primarily due to the loss of healthy parenchymal volume during resection of the tumor.
- Conditions
- Partial Nephrectomy, Kidney Cancer, Renal Function Aggravated
- Trial name
- NCT03323021
- Testing
- Dehydrated human amnion/chorion membrane, Standard of Care
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- MiMedx Group, Inc.
Surgery, Oral
Guided Bone Regeneration Using Polydioxanone (PDO) Membrane in Sockets After Tooth Extraction
The goal of this clinical trial is to compare the maintenance of socket volume in the groups treated by a resorbable regenerative membrane (Plenum® Guide) covered or not with mucous tissue, with control without treatment.
- Trial name
- NCT06015906
- Testing
- Plenum® Guide, Plenum® Oss, Tooth extraction
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- M3 Health
Primary Membranous Nephropathy
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the…
- Trial name
- NCT05668403
- Testing
- B007
- Where
- 6 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs)
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
This retrospective multi-site observational cohort study uses electronic health records (EHR) from U.S. wound care centers to evaluate the effectiveness of four amniotic membrane allografts (Acesso DL, Acesso TL, Neostim DL…
- Conditions
- Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
- Trial name
- HEAL-4 (NCT07223515)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Dynamic Medical Services dba Acesso Biologics
Lupus Membranous Nephropathy
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
- Trial name
- NCT03285711
- Testing
- Filgotinib, Lanraplenib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Primary Membranous Nephropathy
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
- Trial name
- NCT06470191
- Testing
- B007, Cyclosporin Capsules
- Where
- 21 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Peri-implantitis
Treatment of Peri-implantitis Lesions by Using Biomaterial
The primary objective of the study is to proof the successful use of Geistlich Bio-Oss® and Geistlich Bio-Gide® (already registered medical devices) in bony peri-implant defects due to peri-implantitis disease.
- Trial name
- NCT02375750
- Testing
- GBO and GBG, Standard treatment
- Where
- Sweden
- Volunteers
- 71 people
- Sponsor
- Geistlich Pharma AG
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Prostatic Cancer, Castration-Resistant
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617)…
- Trial name
- NCT07047118
- Testing
- JSB462, AAA617
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 138 people
- Sponsor
- Novartis Pharmaceuticals
Primary Membranous Nephropathy
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
- Trial name
- MAJESTY (NCT04629248)
- Testing
- Obinutuzumab, Tacrolimus, Methylprednisolone
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM US (NCT07122193)
- Testing
- NT 201
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Merz North America, Inc.